Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1654 1658
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18276122 | Lipocalin 10 and its Truncated Protein as Therapeutic Agents for Inflammation-Induced Organ Dysfunction | Non-Final OA | University of Cincinnati |
| 18253146 | EXTREMELY FAST SOLID PHASE SYNTHESIS | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 17614231 | EFFICIENT METHOD FOR PREPARING PPR PROTEIN AND USE OF THE SAME | Non-Final OA | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
| 18324461 | COMPOSITION AND METHOD OF TREATING BRAIN CANCER | Non-Final OA | Morehouse School of Medicine |
| 18246572 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HAIR LOSS AND OTHER CONDITIONS | Non-Final OA | ProTransit Nanotherapy LLC |
| 18010399 | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE | Non-Final OA | Chong Kun Dang Pharmaceutical Corp. |
| 18551020 | FERRITIN VARIANTS WITH INCREASED STABILITY AND COMPLEXATION ABILITY | Non-Final OA | Cellis AG |
| 18263431 | NOVEL SELECTIVE ANTIMICROBIAL FUSION PEPTIDES | Non-Final OA | BOMBI BIOMICS BV |
| 18299620 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | Non-Final OA | Xygenyx Inc. |
| 17289848 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Non-Final OA | Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences |
| 18141298 | PEPTIDES AND CONJUGATES THEREOF AS ACE-2 AND S1 SUBUNIT MIMICS AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV2) INFECTION | Non-Final OA | NEUOME PEPTIDES PTE. LTD. |
| 18185167 | FUSION PEPTIDES CONTAINING DIMERIC ALPHA-HELICES, PEPTIDE-MOLECULARCONJUGATES CONTAINING THE SAME AND NUCLEIC ACID DELIVERY COMPOSITIONSCONTAINING THE SAME | Non-Final OA | Artprobio Co., Ltd. |
| 18165613 | CELL MEMBRANE PENETRATING CONJUGATES | Non-Final OA | CYGENICA LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy